@article{885beb6a29074ef38e0e97a2c16d0f10,
title = "Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study",
abstract = "Objective: Identify clinical features predictive of Lewy body pathology in Alzheimer's disease (AD) patients in an ongoing longitudinal clinicopathologic study. Material and Methods: We queried the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) database for dementia cases with AD pathology (1997-2015). Subjects received longitudinal comprehensive clinical evaluations including motor/neuropsychological assessment and Apo-E4 genotyping. All cases were autopsied and had standard neuropathological assessments for AD and Lewy-type synucleinopathy (LTS). Subjects were categorized based on standardized pathological criteria with AD cases that had LTS but did not meet DLB pathologic criteria being categorized as ADLB. We performed pairwise comparison between the different diagnoses and multivariable modelling to identify clinical symptoms that predict the pathological diagnosis. Results: We identified 32 DLB/AD, 54 ADLB, 70 AD only and 41 PDD/AD cases. AD subjects with LTS pathology had higher UPDRS II and III total scores as well as generally higher individual scores compared to AD alone. While depression scales and Trail-making Test A correlated significantly with LTS, other neuropsychological variables were not significantly different. Apo E4 occurrence was similar in all groups (40%-49%). Conclusions: Our study suggests that the presence (or absence) of LTS influences motor and non-motor clinical findings in AD patients. These findings may lead to biomarkers that allow for more targeted treatment of AD.",
keywords = "Alzheimer's disease, Lewy bodies, neuropsychology, pathology",
author = "Rodolfo Savica and Beach, {Thomas G.} and Hentz, {Joseph G.} and Sabbagh, {Marwan N.} and Serrano, {Geidy E.} and Sue, {Lucia I.} and Dugger, {Brittany N.} and Shill, {Holly A.} and Erika Driver-Dunckley and Caviness, {John N.} and Mehta, {Shyamal H.} and Jacobson, {Sandra A.} and Belden, {Christine M.} and Davis, {Kathryn J.} and Edward Zamrini and Shprecher, {David R.} and Adler, {Charles H.}",
note = "Funding Information: RS: receives research support from NIH. TGB: receives grant support from the Arizona Alzheimer{\textquoteright}s Consortium, National Institutes of Health and MJFF, performs contracted research for Navidea Biopharamaceuticals, Avid Radiopharmaceuticals and Aprinoia Therapeutics, and serves as a paid consultant with Genentech, GSK, Prothena, Roche and Ventana. JGH: received re‐ search grant funding for this project from the NIH. MNS: receives consulting fees from Axovant, Biogen, Grifols, Humana, Lilly, Sanofi, vTv Therapeutics, AstraZeneca, Avid Pharmaceuticals, Aovant, Genentech, Lilly, Merk, Pfizer, Roche Diagnostics, vTv Therapeutics, Piramal Imaging; and owns stock in Brain Health, Muses Labs, and Versanum. GS: receives research support from Arizona Biomedical Research Commission. LIS, EDD, SAJ, KJD, EZ: report no disclosures. BND: has received funding support from grants from the National Institutes of Health, as well as the CurePSP Foundation, the Alzheimer{\textquoteright}s Association, the Henry M. Jackson Foundation and Daiichi Sankyo Co., Ltd. HAS: received research support from Cynapsus/Sunovion, Axovant, Impax, US World Meds, Michael J. Fox Foundation and the NIH. JNC: receives research support from MJFF and Pfizer. SHM: receives consult‐ ing fees from Abbvie, Medtronic, and Adamas and research sup‐ port from Jazz Pharmaceuticals, Pharma 2B, Eli Lily and Arizona Biomedical Research Consortium (ABRC). CMB: receives research support from the Arizona Alzheimer{\textquoteright}s Consortium, National Institutes of Health, MJFF, Axovant, Biogen, Lilly, Avid, Genentech, AstraZeneca, Merck, Pfizer, Roche, Takeda, Biotie, Neurocrine, Navidea, Novartis, Suven, Abbvie, USC‐ALZ Association and Navidea. DRS: received research support from the Acorda, Arizona Alzheimer{\textquoteright}s Consortium, Axovant, Biogen, Intec, Teva, Neurocrine, Michael J Fox Foundation, and NIH; consultant fees from Eli Lilly, Teva, Lundbeck and Weston Brain Institute; speaker fees from Acadia, the Arizona Psychiatric Society, Lundbeck, Teva and the Tourette Association of America. CHA: has received research funding from the Michael J. Fox Foundation, NIH, US Department Funding Information: Funding information This study was funded by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium), the Michael J. Fox Foundation for Parkinson's Research and Mayo Clinic Foundation. The authors thank Ms. Lea Dacy for proofreading and formatting assistance. Funding Information: This study was funded by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson{\textquoteright}s Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer{\textquoteright}s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer{\textquoteright}s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05‐901 and 1001 to the Arizona Parkinson{\textquoteright}s Disease Consortium), the Michael J. Fox Foundation for Parkinson{\textquoteright}s Research and Mayo Clinic Foundation.",
year = "2019",
month = jan,
doi = "10.1111/ane.13028",
language = "English (US)",
volume = "139",
pages = "76--81",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "1",
}